These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 6287653

  • 1. Susceptibility of dermatiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination.
    Corrado ML, Kramer M, Cummings M, Eng RH.
    Sabouraudia; 1982 Jun; 20(2):109-13. PubMed ID: 6287653
    [Abstract] [Full Text] [Related]

  • 2. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.
    Odds FC.
    Antimicrob Agents Chemother; 1982 Nov; 22(5):763-70. PubMed ID: 6295266
    [Abstract] [Full Text] [Related]

  • 3. Susceptibility of zygomycetes to amphotericin B, miconazole, and ketoconazole.
    Eng RH, Person A, Mangura C, Chmel H, Corrado M.
    Antimicrob Agents Chemother; 1981 Nov; 20(5):688-90. PubMed ID: 6275783
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients.
    Moody MR, Young VM, Morris MJ, Schimpff SC.
    Antimicrob Agents Chemother; 1980 May; 17(5):871-5. PubMed ID: 6249197
    [Abstract] [Full Text] [Related]

  • 5. Cutaneous phaeohyphomycosis of the sole caused by Exophiala jeanselmei and its susceptibility to amphotericin B, 5-FC and ketoconazole.
    Hironaga M, Mochizuki T, Watanabe S.
    Mycopathologia; 1982 Aug 20; 79(2):101-4. PubMed ID: 6290889
    [No Abstract] [Full Text] [Related]

  • 6. In vitro evaluation of antifungal combinations against neurotropic dematiaceous fungi associated with primary cerebral phaeohyphomycosis.
    Samaddar A, Mendonsa JM, Sudhaharan S, S N, Kindo AJ, Shetty A, Pamidimukkala U.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0078124. PubMed ID: 38920376
    [Abstract] [Full Text] [Related]

  • 7. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.
    Hughes CE, Harris C, Moody JA, Peterson LR, Gerding DN.
    Antimicrob Agents Chemother; 1984 May 06; 25(5):560-2. PubMed ID: 6329088
    [Abstract] [Full Text] [Related]

  • 8. [In vitro antifungal susceptibility of dematiaceous filamentous fungi using the E-test].
    Vivas JR, Torres-Rodríguez JM.
    Rev Esp Quimioter; 2001 Jun 06; 14(2):191-7. PubMed ID: 11704774
    [Abstract] [Full Text] [Related]

  • 9. In vitro susceptibility of Paracoccidioides brasiliensis yeast form to antifungal agents.
    Restrepo A, Tabares Cde B.
    Rev Inst Med Trop Sao Paulo; 1984 Jun 06; 26(6):322-8. PubMed ID: 6100138
    [No Abstract] [Full Text] [Related]

  • 10. Antifungal agents useful in therapy of systemic fungal infections.
    Medoff G, Brajtburg J, Kobayashi GS, Bolard J.
    Annu Rev Pharmacol Toxicol; 1983 Jun 06; 23():303-30. PubMed ID: 6307124
    [No Abstract] [Full Text] [Related]

  • 11. In vitro comparison of the antifungal activities of R34,000, miconazole and amphotericin B.
    Dixon DM, Wagner GE, Shadomy S, Shadomy HJ.
    Chemotherapy; 1978 Jun 06; 24(6):364-7. PubMed ID: 699677
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of antifungal agents against yeast species.
    Bergan T, Vangdal M.
    Chemotherapy; 1983 Jun 06; 29(2):104-10. PubMed ID: 6301773
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp.
    Hernández Molina JM, Llosá J, Martinez Brocal A, Ventosa A.
    Mycopathologia; 1992 Apr 06; 118(1):15-21. PubMed ID: 1406898
    [Abstract] [Full Text] [Related]

  • 14. [Comparative study of two systems for the determination of the sensitivity of yeasts to antifungal agents].
    de Montclos M, de Montclos H, Flandrois JP.
    Pathol Biol (Paris); 1992 May 06; 40(5):495-9. PubMed ID: 1495833
    [Abstract] [Full Text] [Related]

  • 15. In vitro antifungal susceptibility of fungi isolated from respiratory tract of patients and other sources.
    Chaturvedi VP, Chaturvedi S, Khan ZU, Randhawa HS.
    Indian J Chest Dis Allied Sci; 1988 May 06; 30(1):36-40. PubMed ID: 3169869
    [No Abstract] [Full Text] [Related]

  • 16. In vitro antifungal susceptibilities of Scopulariopsis isolates.
    Aguilar C, Pujol I, Guarro J.
    Antimicrob Agents Chemother; 1999 Jun 06; 43(6):1520-2. PubMed ID: 10348787
    [Abstract] [Full Text] [Related]

  • 17. In vitro susceptibilities to amphotericin B, itraconazole, and miconazole of filamentous fungi isolated from patients with cystic fibrosis.
    Hennequin C, Benailly N, Silly C, Sorin M, Scheinmann P, Lenoir G, Gaillard JL, Berche P.
    Antimicrob Agents Chemother; 1997 Sep 06; 41(9):2064-6. PubMed ID: 9303420
    [Abstract] [Full Text] [Related]

  • 18. "In vitro" evaluation of Aspergillus susceptibility to antifungal agents.
    Viviani MA, Tortorano AM.
    Ann Sclavo; 1982 Sep 06; 24(6):642-50. PubMed ID: 6320751
    [No Abstract] [Full Text] [Related]

  • 19. In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole.
    Ahearn DG, McGlohn MS.
    J Clin Microbiol; 1984 Mar 06; 19(3):412-6. PubMed ID: 6325491
    [Abstract] [Full Text] [Related]

  • 20. Susceptibility testing of medically important fungi.
    Merz WG.
    Adv Exp Med Biol; 1986 Mar 06; 202():127-34. PubMed ID: 3788693
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.